This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023 when it reached 21% positivity, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and is coming to an end with positivity falling below the 10% seasonal threshold in week 16/2023 (9%).
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023 before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing again to 10% positivity in week 15/2023.